“There are, indeed, numerous paths that we are trying to tackle from different angles,” says Gennady Bratslavsky, MD.
In this video, Gennady Bratslavsky, MD, discusses key research that will be clinically significant in the renal cell carcinoma space. These ideas are associated with a presentation he gave at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Bratslavsky is a Phillip Capozzi M.D. Endowed Professor of Urology, chair of urology, and director of the prostate cancer program at SUNY Upstate Medical University in Syracuse, New York.
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
May 15th 2024The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
April 29th 2024“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.